Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | CLARITY: a Phase 2 trial using venetoclax and ibrutinib

CLARITY is a Phase II clinical trial studying the combination of ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL). In this video, Francesco Forconi, MD, DM, PhD, FRCPath from the University of Southampton, Southampton, UK discusses the results presented at the American Socienty of Hematology (ASH) 2017 Annual Meeting, held in Atlanta, GA.